[go: up one dir, main page]

ES2107980T1 - Medio para tratar enfermedades autoinmunes y metodo de tratamiento. - Google Patents

Medio para tratar enfermedades autoinmunes y metodo de tratamiento.

Info

Publication number
ES2107980T1
ES2107980T1 ES95913445T ES95913445T ES2107980T1 ES 2107980 T1 ES2107980 T1 ES 2107980T1 ES 95913445 T ES95913445 T ES 95913445T ES 95913445 T ES95913445 T ES 95913445T ES 2107980 T1 ES2107980 T1 ES 2107980T1
Authority
ES
Spain
Prior art keywords
autoimmune diseases
treat autoimmune
treatment
glycoprotein beta
trofoblastic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ES95913445T
Other languages
English (en)
Inventor
Ivan Nikolaevich Golovistikov
Leonid Yazonovich Kacharava
Jury Semyonovich Tatarinov
Khallar Abdumuslimov Alikhanov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of ES2107980T1 publication Critical patent/ES2107980T1/es
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • External Artificial Organs (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

EL ELEMENTO PROPUESTO PARA TRATAR ENFERMEDADES AUTOINMUNES CON UN INMUNODEFICIT DE CELULAS SUPRESORAS ES GLICOPROTEINA BETA-1 TROFOBLASTICA. EL METODO PROPUESTO PARA TRATAR ENFERMEDADES AUTOINMUNOLOGICAS IMPLICA LA ADMINISTRACION DE UN AGENTE INMUNOCORRECTOR, ESPECIFICAMENTE, GLICOPROTEINA BETA-1 TROFOBLASTICA; SE OBTIENEN INDICADORES PARA USAR DICHO AGENTE MEDIANTE EL ANALISIS DE CELULAS MONOCUCLEARES RESPECTO A SU SENSIBILIDAD A LA GLICOPROTEINA BETA-1 TROFOBLASTICA.
ES95913445T 1994-03-18 1995-03-16 Medio para tratar enfermedades autoinmunes y metodo de tratamiento. Pending ES2107980T1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU9494008169A RU2056852C1 (ru) 1994-03-18 1994-03-18 Средство для лечения аутоиммунных заболеваний с иммунодефицитом супрессоров и способ лечения аутоиммунных заболеваний

Publications (1)

Publication Number Publication Date
ES2107980T1 true ES2107980T1 (es) 1997-12-16

Family

ID=20153349

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95913445T Pending ES2107980T1 (es) 1994-03-18 1995-03-16 Medio para tratar enfermedades autoinmunes y metodo de tratamiento.

Country Status (22)

Country Link
US (1) US6150326A (es)
EP (1) EP0790059B1 (es)
JP (1) JPH09510473A (es)
KR (1) KR100382252B1 (es)
CN (1) CN1146156A (es)
AT (1) ATE260111T1 (es)
AU (1) AU699896B2 (es)
BG (1) BG62759B1 (es)
CA (1) CA2185892A1 (es)
CZ (1) CZ285856B6 (es)
DE (2) DE69532611D1 (es)
ES (1) ES2107980T1 (es)
FI (1) FI963671A7 (es)
GE (1) GEP20012377B (es)
GR (1) GR980300023T1 (es)
HU (1) HUT75720A (es)
NO (1) NO963911L (es)
PL (1) PL179765B1 (es)
RU (1) RU2056852C1 (es)
SK (1) SK281948B6 (es)
UA (1) UA26939C2 (es)
WO (1) WO1995025531A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2120298C1 (ru) * 1995-11-28 1998-10-20 Товарищество с ограниченной ответственностью "Верта" Иммуностимулятор и препарат на его основе
FR2747041B1 (fr) * 1996-04-05 1998-05-22 Cird Galderma Utilisation de derives benzonaphtaleniques pour la fabrication de medicaments destines au traitement des neuropathies
GB0030729D0 (en) * 2000-12-16 2001-01-31 Univ Nottingham Substituted-4-Quinolones
US20050032725A1 (en) * 2002-10-09 2005-02-10 Toerrx, Inc. Molecules preferentially associated with effector T cells or regulatory T cells and methods of their use
RU2303995C1 (ru) * 2006-04-28 2007-08-10 Халлар Абдумуслимович Алиханов Средство, обладающее иммунорегуляторным свойством и его применение для лечения аутоиммунных заболеваний

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1107772B (it) * 1977-08-22 1985-11-25 Cancer Res Inst Royal Procedimento per la produzione di complessi macromolecolari prodotto ottenuto e composizioni farmaceutiche che lo contengono come ingrediente attivo
JPS61186322A (ja) * 1985-02-13 1986-08-20 Nippon Univ 免疾調節剤
IT1188646B (it) * 1986-04-09 1988-01-20 Ellem Ind Farmaceutica Tripeptide ad attivita' immunostimolante
US4803072A (en) * 1986-09-10 1989-02-07 Smithkline Beckman Corporation Immunomodulation
FR2609632B1 (fr) * 1987-01-21 1991-03-29 Shelly Marc Nouvelle application therapeutique de la 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinon-6-one et les compositions pharmaceutiques destinees a cet usage
US5169835A (en) * 1989-01-18 1992-12-08 Oklahoma Medical Research Foundation Pregancy specific proteins applications
FR2650183A1 (fr) * 1989-07-25 1991-02-01 Pasteur Institut Proteines immunostimulantes, anticorps monoclonaux et polyclonaux correspondants, hybridomes correspondants et application de ces produits a des fins therapeutiques et de diagnostic
US5118669A (en) * 1989-09-20 1992-06-02 Hitachi Chemical Co., Ltd. Peptides and intermediates therefor useful as antiallergic agents, vasodilators and immunoregulators
US5559097A (en) * 1990-01-12 1996-09-24 Idaho Research Foundation, Inc. Use of a pregnancy specific protein as an immunosuppressive
RU1836957C (ru) * 1990-03-25 1993-08-30 2-й Московский государственный медицинский институт им.Н.И.Пирогова Способ получени трофобластического бета @ -гликопротеина
GB2251186A (en) * 1990-12-04 1992-07-01 Randall Neal Gatz Polypeptide for use in treatment of autoimmune disease

Also Published As

Publication number Publication date
BG100921A (bg) 1997-12-30
RU2056852C1 (ru) 1996-03-27
EP0790059A1 (en) 1997-08-20
CA2185892A1 (en) 1995-09-28
CZ274796A3 (en) 1997-06-11
FI963671L (fi) 1996-11-14
NO963911D0 (no) 1996-09-18
KR100382252B1 (ko) 2003-07-07
UA26939C2 (uk) 1999-12-29
NO963911L (no) 1996-11-08
EP0790059B1 (en) 2004-02-25
EP0790059A4 (en) 2000-11-02
HU9602558D0 (en) 1996-11-28
BG62759B1 (bg) 2000-07-31
DE69532611D1 (de) 2004-04-01
DE790059T1 (de) 1998-03-12
PL179765B1 (pl) 2000-10-31
SK281948B6 (sk) 2001-09-11
WO1995025531A1 (en) 1995-09-28
JPH09510473A (ja) 1997-10-21
HUT75720A (en) 1997-05-28
CZ285856B6 (cs) 1999-11-17
ATE260111T1 (de) 2004-03-15
SK118796A3 (en) 1997-06-04
KR970701557A (ko) 1997-04-12
CN1146156A (zh) 1997-03-26
AU699896B2 (en) 1998-12-17
FI963671A7 (fi) 1996-11-14
AU2087495A (en) 1995-10-09
US6150326A (en) 2000-11-21
GEP20012377B (en) 2001-03-25
GR980300023T1 (en) 1998-04-30
PL316311A1 (en) 1997-01-06
FI963671A0 (fi) 1996-09-17

Similar Documents

Publication Publication Date Title
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
TR199902124T2 (xx) �ltihapl� hastal�klar�n tedavisinde yararl� k���k molek�ller.
DE69923671D1 (de) Verwendung von kannabidiol als entzündunghemmende mittel
BR9610838A (pt) Processo para tratar um indivìduo tendo uma condição patológica envolvendo neovascularização.
ES2102860T3 (es) Tratamiento cosmetico de substratos.
IT8622795A0 (it) Metodo per un efficace trattamento idratante della pelle, particolarmente per applicazione in campo cosmetico.
BR8907770A (pt) Solucao para tratamento de metal,solucao aquosa e processo para tratar uma superficie de metal
ES2170869T3 (es) Composicion para el tratamiento de las materias queratinicas que comprenden al menos un polimero siliconado injertado y al menos un polimero o copolimero espesante de (met)acrilamida o de un derivado de (met)acrilamida y sus aplicaciones.
ES2107980T1 (es) Medio para tratar enfermedades autoinmunes y metodo de tratamiento.
DE69007374D1 (de) Injektionssystem für die Behandlung von Zellen.
EP0956030A4 (en) THERAPEUTIC APPLICATIONS OF T-BAM TECHNOLOGY (CD40L) FOR THE TREATMENT OF DISEASES RELATED TO SMOOTH MUSCLE CELLS
ES2149448T3 (es) Agentes terapeuticos y analiticos.
EA199800821A1 (ru) Способ лечения аутизма
DE69628153D1 (de) Verwendung von natriumchlorid zur behandlung der akne und/oder der rosacea
ES2126641T3 (es) Utilizacion de fragmentos de protrombinas.
PT1070022E (pt) Dispositivo para o tratamento de agua
JPS51121530A (en) Toiletries
BR8904924A (pt) Composicao de tratamento de couro,sua utilizacao,processo para tratamento de couros,bem como couro assim tratado
ATE213644T1 (de) Kombinationstherapie für die behandlung von arthritis erkrankungen
DK0659079T3 (da) Transdermalt terapeutisk system med pentylentetrazol som aktivt stof.
EA199800822A1 (ru) Способ лечения избыточной агрессии
PT1017377E (pt) Utilizacao de 2-aminotetralinas 6,7-substituidas para o tratamento de condicoes inflamatorias mediadas por citoquina
BR0015424A (pt) Análogos de ácido hidroxieicosatetraenóico e, métodos de seu uso em tratamento de distúrbios de olho seco
TR199800705T2 (es)
UA31956A (uk) Спосіб оцінки ефективності лікування хворих на псоріаз і псоріатичний артрит